China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
IRVINE, Calif., Aug. 28, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE:EVHC). Investors who purchased or otherwise acquired shares between March 2, 2015 and July 21, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 3, 2017 lead plaintiff motion deadline.
If you purchased shares of Envision during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Envision made materially false and/or misleading statements, and/or failed to disclose material information, to investors. On July 24, 2017, The New York Times reported that hospitals associated with the Company’s subsidiary, EmCare Holdings, Inc., were disproportionately likely to engage in “surprise billing,” in which patients who sought treatment at in-network facilities were treated by out-of-network physicians and subsequently billed at higher rates. When this information reached the public, shares of Envision dropped in value materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
